A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome

TY - JOUR

T1 - A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome

AU - Pritchard, J

AU - Gray, I A

AU - Idrissova, Z R

AU - Lecky, B R F

AU - Sutton, I J

AU - Swan, A V

AU - Willison, H J

AU - Winer, J B

AU - Hughes, R A C

PY - 2003

Y1 - 2003

N2 - The authors recruited 19 nonambulant patients with Guillain- Barree syndrome into a pilot, double- blind, randomized, placebo- controlled safety trial of interferon beta 1a ( IFN beta- 1a) ( Rebif). Participants received IFN beta- 1a or placebo subcutaneously three times weekly, 22 mu g for the first week and then 44 mu g for up to 24 weeks, in addition to IV immunoglobulin ( IVIg). IFN beta did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.

AB - The authors recruited 19 nonambulant patients with Guillain- Barree syndrome into a pilot, double- blind, randomized, placebo- controlled safety trial of interferon beta 1a ( IFN beta- 1a) ( Rebif). Participants received IFN beta- 1a or placebo subcutaneously three times weekly, 22 mu g for the first week and then 44 mu g for up to 24 weeks, in addition to IV immunoglobulin ( IVIg). IFN beta did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.

M3 - Article

SN - 1526-632X

VL - 61

SP - 1282

EP - 1284

JO - Neurology

JF - Neurology

IS - 9

ER -